Authorized purpose: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected IPH, IVH, SAH, and SDH findings in non-enhanced head CT images.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected IPH, IVH, SAH, and SDH findings in non-enhanced head CT images.
Overview status: Source-reviewed overview
What does this software do?Authorized purpose: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected IPH, IVH, SAH, and SDH findings in non-enhanced head CT images.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain; suspected intraparenchymal, intraventricular, subarachnoid, and subdural intracranial hemorrhage. Input: Non-enhanced head CT/NCCT images processed through the Rapid Platform's DICOM services.
Who uses it?Intended users: Hospital networks and trained radiologists; notified radiologists must review the full images under the standard of care.
What does the software produce?Output: Priority notifications for cases with suspected IPH, IVH, SAH, or SDH; compressed preview images; and notification delivery through the described PACS, workstation, email, and mobile pathways.
What is its most important limitation?Key limitation: Compressed previews are informational only and not for diagnosis beyond notification. Results must be used with other patient information and professional judgment; notified radiologists must view full images per standard of care. The device is not a diagnostic device and does not alter the original medical image.
Clinical takeaway
Clinical role: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected IPH, IVH, SAH, and SDH findings in non-enhanced head CT images.
Evidence takeaway
Evidence from the reviewed source record: FDA K221456 reports a retrospective, blinded, multicenter, multinational study of 314 NCCT cases (148 ICH-positive and 166 ICH-negative). Overall sensitivity was 96.8% (95% CI 92.6%-98.6%) and specificity was 100% (95% CI 97.7%-100%), exceeding the 80% performance goal. AUC was 0.98632, and time-to-notification was 0.65 minutes (95% CI 0.63-0.67) versus standard-of-care time-to-exam-open 72.58 minutes (95% CI 45.02-100.14); these are distinct endpoints. Subgroup results were reported by age, gender, hemorrhage subtype, volume, slice thickness, scanner manufacturer, make/model, and reconstruction method.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected IPH, IVH, SAH, and SDH findings in non-enhanced head CT images.
Triage and notification prioritization; the device does not alter the original image and provides a compressed preview for notification rather than diagnosis.
Priority notifications for cases with suspected IPH, IVH, SAH, or SDH; compressed preview images; and notification delivery through the described PACS, workstation, email, and mobile pathways.
Compressed previews are informational only and not for diagnosis beyond notification. Results must be used with other patient information and professional judgment; notified radiologists must view full images per standard of care. The device is not a diagnostic device and does not alter the original medical image.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The Rapid Platform provides DICOM processing, job management, imaging execution, notifications, and compressed-image output; the packet lists PACS, workstation, email, and mobile notification pathways. It does not establish a universal local interface, hosting model, or PACS/RIS/EHR version compatibility.
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K221456 reports a retrospective, blinded, multicenter, multinational study of 314 NCCT cases (148 ICH-positive and 166 ICH-negative). Overall sensitivity was 96.8% (95% CI 92.6%-98.6%) and specificity was 100% (95% CI 97.7%-100%), exceeding the 80% performance goal. AUC was 0.98632, and time-to-notification was 0.65 minutes (95% CI 0.63-0.67) versus standard-of-care time-to-exam-open 72.58 minutes (95% CI 45.02-100.14); these are distinct endpoints. Subgroup results were reported by age, gender, hemorrhage subtype, volume, slice thickness, scanner manufacturer, make/model, and reconstruction method.
Overall Rapid ICH sensitivity: 96.8% (95% CI 92.6%-98.6%) in the FDA retrospective blinded multicenter/multinational study of 314 NCCT cases, with 148 ICH-positive and 166 ICH-negative cases.
FDA source
Exact FDA submission
Checked 2026-09-09
The 80% figure is the prespecified performance goal, not the observed sensitivity; AUC, subtype results, and time-to-notification are separate endpoints.
Overall Rapid ICH specificity: 100% (95% CI 97.7%-100%) in the same 314-case NCCT study.
FDA source
Exact FDA submission
Checked 2026-09-09
This preserves the overall specificity endpoint and prevents the active-row 98.6% sensitivity confidence bound or 80% goal from being presented as specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
RapidICH regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K221456
Samplen=314
IndependenceIndependence not established
K221456
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-09
No public price or quote for the exact K221456 configuration was established in this review.
Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-09
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K221456. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Verify pricing and total cost: No public price or quote for the exact K221456 configuration was established in this review.
Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
4Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 4 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history7 sources - 3 history items
Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during...
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2...